Vanda Pharmaceuticals Short Long Term Debt Total Over Time
| VNDA Stock | USD 5.09 0.15 3.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vanda Pharmaceuticals Performance and Vanda Pharmaceuticals Correlation. Vanda |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (0.19) | Revenue Per Share 3.293 | Quarterly Revenue Growth 0.228 | Return On Assets (0.04) |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare Vanda Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Vaxcyte, and Liquidia Technologies Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMRN | 100 K | 348.3 M | 348.2 M | 655.6 M | 1.3 B | 662.3 M | 683.2 M | 1.2 B | 830.4 M | 848.1 M | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 576.8 M |
| LQDA | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 23.5 M | 12.8 M | 24.4 M | 17.1 M | 16.1 M | 24.5 M | 3.5 M | 3.3 M |
| LEGN | 269 K | 269 K | 269 K | 269 K | 269 K | 269 K | 269 K | 269 K | 4.3 M | 6.1 M | 3.4 M | 123 M | 284.5 M | 328.7 M | 345.1 M |
| TECH | 600 K | 12.9 M | 12.9 M | 12.9 M | 116 M | 133.8 M | 349.9 M | 347.9 M | 505.2 M | 433.5 M | 420.6 M | 326 M | 455 M | 419.5 M | 440.5 M |
| NUVB | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 4.3 M | 4 M | 4.2 M |
| TIL | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 79.9 M | 86.1 M | 91.3 M |
| CNTB | 882 K | 882 K | 882 K | 882 K | 882 K | 882 K | 882 K | 882 K | 882 K | 882 K | 139.9 K | 124.5 K | 437.9 K | 465 K | 327.9 K |
| RCUS | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 116.9 M | 120 M | 11 M | 10.4 M |
| CGEM | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 3.6 M | 3.5 M |
| ANNX | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 32.9 M | 31.4 M | 26.3 M |
| GPCR | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 621 | 260 K | 5.5 M | 5.7 M |
| RLAY | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 24.8 M | 24.4 M | 22.9 M | 57.7 M | 53.5 M | 33.6 M |
| STOK | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 80 K | 1.5 M | 2.4 M | 6.8 M | 7.2 M |
| TSVT | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 133.6 M | 127.6 M | 282.2 M | 270.2 M | 256.7 M | 235.5 M |
| KZR | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 5.5 M | 14 M | 21.3 M | 18.9 M | 14.5 M |
| PHAT | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 23.6 M | 49 M | 91.3 M | 97.1 M | 139 M | 73.7 M |
| REPL | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 41.8 M | 33.3 M | 32.8 M | 60.8 M | 75.9 M | 46 M |
| RVMD | 318 K | 318 K | 318 K | 318 K | 318 K | 318 K | 318 K | 318 K | 318 K | 172 K | 32.7 M | 66.6 M | 64.2 M | 87.9 M | 46.2 M |
| BPMC | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 9 M | 7.9 M | 4.6 M | 16.3 M | 14.6 M | 95.9 M | 89.6 M | 111.4 M | 562.7 M | 774.1 M | 812.8 M |
| CYTK | 1.1 M | 3 K | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 29.9 M | 37 M | 42.4 M | 136.1 M | 138.9 M | 269.9 M | 749.3 M | 755.8 M | 793.6 M |
Vanda Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Vaxcyte, and Liquidia Technologies Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| Vanda Pharmaceuticals | VNDA |
| Classification | Pharmaceutical Products |
| Location | District Of Columbia; U.S.A |
| Exchange | NASDAQ Exchange |
USD 5.09
Check out Vanda Pharmaceuticals Performance and Vanda Pharmaceuticals Correlation. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Vanda Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.